A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

NCT Number	NCT07589244
Lead Sponsor	Guangzhou Virotech Pharmaceutical Co., Ltd.
Conditions	HCC
Enrollment	66 participants
Start Date	2026-05-13
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-15